{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"Definition of relapse was \\>5 % blasts in bone marrow","groups":[{"description":"Group I (observation): Patients with full donor chimerism and no evidence of MRD continue to undergo clinical monitoring for acute and chronic graft-vs-host disease and relapse until 3 years post-transplant. Patients undergo repeat chimerism testing at 12 and 24 months post-transplant.","id":"OG000","title":"Group I: Observation"},{"description":"Group II (intervention): Patients undergo withdrawal of immunosuppression and receive donor lymphocyte infusions between days 60-365 post-transplant (or until full donor chimerism is achieved). Patients also undergo clinical monitoring and repeat chimerism testing as in group I.\n\nWithdrawal of immunosuppression and donor lymphocyte infusion: Intervention will involve fast withdrawal of immunosuppression and DLI until full donor chimerism is achieved.","id":"OG001","title":"Group II: Intervention"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years post transplant.","title":"Relapse at 2 Years Post-transplant.","type":"PRIMARY","unitOfMeasure":"participants"}